TriSalus Life Sciences, Inc.
TLSI
$4.73
$0.368.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 115.78% | 9.79% | -30.44% | 20.12% | -2.64% |
| Total Depreciation and Amortization | 7.14% | -22.70% | -1.21% | -4.07% | -10.88% |
| Total Amortization of Deferred Charges | 4.96% | 2.55% | 7.00% | 9.36% | 32.02% |
| Total Other Non-Cash Items | -218.33% | 72.81% | 121.15% | -50.03% | 8.62% |
| Change in Net Operating Assets | 155.85% | -122.20% | 271.97% | -186.80% | 242.40% |
| Cash from Operations | -160.87% | 33.03% | 49.33% | -62.70% | 21.17% |
| Capital Expenditure | -243.90% | 81.02% | -332.26% | 112.33% | -1,408.00% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -243.90% | 76.70% | -289.25% | 113.03% | -1,328.00% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -200.00% | 50.00% | -500.00% | 98.59% | -273.68% |
| Issuance of Common Stock | 15,134.64% | 218.18% | -99.60% | 7,881.00% | -90.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -197.88% | -- |
| Cash from Financing | 15,201.44% | 237.80% | -99.60% | 113.84% | 223.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,690.93% | 40.89% | -128.19% | 201.45% | 261.96% |